Ukoniq (umbralisib) is a medication taken by mouth to treat the blood cancers called marginal zone lymphoma (MZL) and follicular lymphoma (FL). It was approved by the FDA in 2021, but taken off the market shortly after due to safety concerns. It has been discontinued and is no longer available in the United States.
Marginal zone lymphoma (MZL)
Follicular lymphoma (FL)
Certain types of CD20-positive non-Hodgkin’s lymphoma (NHL) in adults and children ages 6 months and older
CD20-positive chronic lymphocytic leukemia (CLL) in adults
Moderate to severe rheumatoid arthritis (RA) in adults
Granulomatosis with polyangitis (GPA) and microscopic polyangitis (MPA) in adults and children ages 2 years and older
Moderate to severe pemphigus vulgaris in adults
By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.